Determinants of response to roflumilast in severe chronic obstructive pulmonary disease: Pooled analysis of two randomized trials

Fernando J. Martinez, Klaus F. Rabe, Peter M.A. Calverley, Leonardo M. Fabbri, Sanjay Sethi, Emilio Pizzichini, Andrew McIvor, Antonio R Anzueto, Vijay K.T. Alagappan, Shahid Siddiqui, Colin Reisner, Sofia Zetterstrand, Jonas Román, Debasree Purkayastha, Nitin Bagul, Stephen I. Rennard

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Rationale: Roflumilast reduces exacerbations in patients with severe chronic obstructive pulmonary disease associated with chronic bronchitis and a history of exacerbations. Further characterization of patients most likely to benefit is warranted. Objectives: Define characteristics that most robustly identify patients who derive greatest exacerbation risk reduction with roflumilast. Methods: Predefined, pooled analyses of REACT (Roflumilast in the Prevention of COPD Exacerbations While Taking Appropriate Combination Treatment; NCT01329029) and RE2SPOND (Roflumilast Effect on Exacerbations in Patients on Dual [LABA/ICS] Therapy; NCT01443845) multicenter, randomized, double-blind, placebo-controlled studies. The primary endpoint was rate of moderate or severe exacerbations per patient per year. Measurements and Main Results: In the overall intention-totreat population (n = 4,287), roflumilast reduced moderate or severe exacerbations by 12.3% (rate ratio, 0.88, 95% confidence interval, 0.80-0.97; P = 0.0086) and severe exacerbations by 16.1% (0.84; 0.71-0.99; P = 0.0409) versus placebo. The reduction in moderate or severe exacerbations with roflumilast was most pronounced in patients who had been hospitalized for an exacerbation in the prior year (0.74; 0.63-0.88; P = 0.0005); had more than two exacerbations in the prior year (0.79; 0.65-0.96; P = 0.0160); or had baseline eosinophils ≥150 cells/μl (0.81; 0.71-0.93; P = 0.0020), ≥150 to ,300 cells/μl (0.84; 0.71-0.98; P = 0.0282), or ≥300 cells/μl (0.77; 0.61-0.97; P = 0.0264). Similar subgroup results were noted for severe exacerbations. In patients with prior hospitalization and higher baseline blood eosinophil concentrations, roflumilast reduced moderate or severe exacerbations by 34.5% at ≥150 cells/μl (0.65; 0.52-0.82; P = 0.0003) and 42.7% at ≥300 cells/μl (0.57; 0.37-0.88; P = 0.0111) versus placebo. Conclusions: This prespecified, pooled analysis confirms the benefit of roflumilast in decreasing exacerbations in patients with prior hospitalization for exacerbation, greater exacerbation frequency, and higher (≥150 cells/μl, ≥150 to <300 cells/μl, or ≥300 cells/μl) baseline blood eosinophil count.

Original languageEnglish (US)
Pages (from-to)1268-1278
Number of pages11
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume198
Issue number10
DOIs
StatePublished - Nov 15 2018

Keywords

  • Cigarette smoking
  • Cough
  • Glucocorticosteroids
  • Inflammation
  • Sputum

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Fingerprint Dive into the research topics of 'Determinants of response to roflumilast in severe chronic obstructive pulmonary disease: Pooled analysis of two randomized trials'. Together they form a unique fingerprint.

  • Cite this

    Martinez, F. J., Rabe, K. F., Calverley, P. M. A., Fabbri, L. M., Sethi, S., Pizzichini, E., McIvor, A., Anzueto, A. R., Alagappan, V. K. T., Siddiqui, S., Reisner, C., Zetterstrand, S., Román, J., Purkayastha, D., Bagul, N., & Rennard, S. I. (2018). Determinants of response to roflumilast in severe chronic obstructive pulmonary disease: Pooled analysis of two randomized trials. American Journal of Respiratory and Critical Care Medicine, 198(10), 1268-1278. https://doi.org/10.1164/rccm.201712-2493OC